Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Angst, Daniela and Gessier, Francois and Janser, Philipp and Pulz, Robert and Vulpetti, Anna and Waelchli, Rudolf and Beerli, Christian and Littlewood-Evans, Amanda and Dawson King, Janet and Nuesslein-Hildesheim, Barbara and Wieczorek, Grazyna and Gutmann, Sascha and Scheufler, Clemens and Hinniger, Alexandra and Zimmerlin, Alfred Gilbert and Funhoff, Enrico and Cenni, Bruno (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry. ISSN 0022-26231520-4804

Abstract

Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in Phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren’s Syndrome.

Item Type: Article
Date Deposited: 21 Mar 2020 00:45
Last Modified: 21 Mar 2020 00:45
URI: https://oak.novartis.com/id/eprint/41466

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.